89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
89bio has raised $287.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2025.
89bio's investors include RA Capital Management, OrbiMed, Longitude Capital, Pontifax, K2 HealthVentures.
89bio is headquartered in San Francisco, United States.
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
89bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"89bio — Funding & Investors." VCBacked, January 28, 2025, https://www.vcbacked.co/company/89bio. Accessed September 9, 2026.
VCBacked. (2025). 89bio — Funding & Investors. Retrieved September 9, 2026, from https://www.vcbacked.co/company/89bio
{{cite web |title=89bio — Funding & Investors |url=https://www.vcbacked.co/company/89bio |website=VCBacked |access-date=September 9, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated